One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Porcine Vaccine Market

[ 英語タイトル ] Porcine Vaccine Market - Growth, Trends, and Forecast (2020 - 2025)

Product Code : MDHC0082914
Survey : Mordor Intelligence
Publish On : November, 2020
Category : Healthcare and Pharmaceuticals
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
- Bayer AG
- IDT Biologika GmbH
- Ceva Sante Animale
- Elanco
- Arko Laboratories Ltd
- Intervet Inc.
- Merial
- Vetoquinol
- Zoetis Inc.

[Report Description]

The recent years have witnessed a significant increase in the demand for pork and gelatin, an increase in the prevalence of swine diseases, and growth in R&D expenditure for innovation of vaccines. According to the world meat consumption statistics provided by the US Department of Agriculture - Foreign Agricultural Service (USDA – FAS), 40.4% of the total meat consumption, across the globe, in 2017 is accounted for by pork alone. The report also states that per capita pork consumption (lb, carcass weight) has observed significant growth, across many regions, as shown in the graph.

This increase in pork consumption is expected to give rise to a growing need of keeping the swine population free from every possible disease that could affect swine and pose a threat to the human population, owing to the rise in prevalence of several zoonotic diseases. As a result of this, the requirement for a variety of swine vaccines, targeting various porcine diseases, is expected to grow.

Key Market Trends

Porcine Circovirus Associated Disease is Expected to Witness a Healthy Growth

PCV (Porcine Circovirus) is the smallest non-enveloped, single-stranded DNA virus, which replicates autonomously in eukaryotic cells, using the host polymerase for genome amplification. Generally, the price of vaccines targeting porcine circovirus associated disease (PCVAD) can range from USD 50 to around USD 500. Commercially available PCVAD vaccines can be of many types, mainly based upon the dosage, packaging size, age of the pig it is used on, and virus type. Some of the major brands manufacturing and selling porcine vaccines for PCVAD, globally, are Boehringer Ingelheim, Merck, and Zoetis, among others. The first FLEX Family swine vaccine for PCV2 protection in a single injection was Ingelvac CircoFLEX, by Boehringer Ingelheim. Hence, it is one of the revolutionary PCV2 vaccines in the market.

United States Holds a Significant Market Share

Increasing pork consumption, the growing prevalence of various swine diseases, and rising per capita animal healthcare expenditure are the factors due to which the United States is expected to retain its large market share.

Europe is the second-largest market for Porcine Vaccine is expected to follow North America, while Asia-Pacific is expected to demonstrate highest growth rate owing to factors such as increasing demand for animal-based food products, especially in South-East Asia, rise in awareness about porcine health, and recent advancements in the field of biotechnology. Hence, the aforementioned factors are expected to fuel the growth of the Porcine Vaccine Market in the Asia Pacific.

Competitive Landscape

The porcine vaccines market is fairly competitive and consists of several major players. Most of these major players enjoy a global presence and are facing intense competition in emerging economies. The emerging countries are becoming hotspots for significant competition, due to a rapidly expanding market size, fueled by rising concerns over food safety and the increasing adoption of companion as well as farm animals.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- Report customization as per the client's requirements
- 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Growth in Demand for Pork and Gelatin
4.2.2 Rise in Prevalence of Swine Diseases
4.2.3 Increase in R&D Expenditure for Innovation of Vaccines
4.3 Market Restraints
4.3.1 High Expenses of Maintaining and Handling Storage Conditions
4.3.2 Chance of Reverse Reaction from Vaccines
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Target Disease
5.1.1 Diarrhea
5.1.2 Swine Influenza
5.1.3 Arthritis
5.1.4 Bordetella Rhinitis
5.1.5 Porcine Reproductive and Respiratory Syndrome (PRRS)
5.1.6 Porcine Circovirus Associated Disease (PCVAD)
5.1.7 Other Target Diseases
5.2 By Technology
5.2.1 Inactivated Vaccines
5.2.2 Live Attenuated Vaccines
5.2.3 Toxoid Vaccines
5.2.4 Recombinant Vaccines
5.2.5 Others
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1.1 Bayer AG
6.1.2 IDT Biologika GmbH
6.1.3 HIPRA
6.1.4 Ceva Sante Animale
6.1.5 Elanco
6.1.6 Arko Laboratories Ltd
6.1.7 Intervet Inc.
6.1.8 Merial
6.1.9 Vetoquinol
6.1.10 Zoetis Inc.




Recommended reports